Clopidogrel

Mechanism

Apixaban directly inhibits factor Xa; clopidogrel blocks the platelet P2Y12 receptor. The two antithrombotic mechanisms add up.

Symptoms

Gum bleeding, epistaxis, bruising without trauma, blood in urine or stool, menorrhagia. Severe cases include gastrointestinal or intracranial haemorrhage. Risk rises in patients over 65 and with prior peptic ulcer disease.

Management

Dual therapy is used after acute coronary syndrome or stenting in atrial fibrillation, generally for no more than 1–6 months. Apixaban dose is selected according to age, weight, and renal function. PPI cover with pantoprazole is mandatory.

Mechanism

Esomeprazole inhibits CYP2C19, the key enzyme that converts clopidogrel to its active metabolite. Active clopidogrel levels fall by about 35%, weakening antiplatelet effect.

Symptoms

The patient feels no symptoms – the weakened antiplatelet effect is silent. The combination raises recurrent myocardial infarction and stent thrombosis risk in patients with prior stenting or acute coronary syndrome.

Management

Replace esomeprazole with pantoprazole (minimal CYP2C19 impact). Among other PPIs, rabeprazole is an alternative. If a PPI is not required, switch to famotidine (H2-blocker) or stop acid suppression.

Mechanism

Fluconazole inhibits CYP2C19, the key enzyme converting clopidogrel into its active metabolite. Active levels fall by 25–50% and the antiplatelet effect weakens.

Symptoms

The patient feels no symptoms – the weakened antiplatelet effect is silent. Risk of recurrent coronary events and stent thrombosis rises.

Management

For a short fluconazole course, the effect is clinically minor. For prolonged systemic therapy (>14 days), an alternative antiplatelet is ticagrelor (not CYP2C19-dependent). Alternative antifungal: echinocandins for systemic mycoses.

Mechanism

Fluoxetine inhibits CYP2C19, the enzyme converting clopidogrel into its active metabolite. Active levels fall and antiplatelet effect weakens. Fluoxetine also depletes the platelet serotonin pool, impairing primary haemostasis.

Symptoms

Dual risk: weakened antiplatelet effect (raising thrombosis risk) alongside increased upper GI bleeding risk.

Management

Alternative antidepressants: sertraline or escitalopram (weaker CYP2C19 inhibitors), or mirtazapine/agomelatine (minimal platelet effect). Alternative antiplatelet: ticagrelor (not CYP2C19-dependent). PPI cover with pantoprazole is mandatory.

Mechanism

Clopidogrel is a prodrug, activated by CYP2C19. Fluvoxamine is a potent CYP2C19 inhibitor. The active clopidogrel metabolite is not formed and antiplatelet effect is lost.

Symptoms

The patient feels no symptoms – the weakened antiplatelet effect is silent. The combination raises recurrent myocardial infarction, stent thrombosis, and stroke risks.

Management

The combination is not prescribed. Alternative antidepressants without CYP2C19 effect: sertraline or escitalopram (moderate but weaker effect), or mirtazapine/agomelatine (no effect). Alternative antiplatelet: ticagrelor (not CYP2C19-dependent).

Mechanism

Clopidogrel is a prodrug. It must be converted in the liver via CYP2C19 into its active antiplatelet metabolite. Omeprazole strongly inhibits CYP2C19: active metabolite levels drop by 45% and platelet inhibition weakens. The FDA issued a dedicated warning about this pair in 2009.

Symptoms

The patient feels no symptoms – the weakened antiplatelet effect is silent. The combination raises the risk of recurrent myocardial infarction, stent thrombosis, and stroke in patients with prior stenting or acute coronary syndrome.

Management

Replace omeprazole with pantoprazole, which has minimal effect on CYP2C19. Among other proton pump inhibitors, rabeprazole is an alternative. If a PPI is not required, switch to famotidine (an H2-blocker that does not affect CYP2C19) or stop acid suppression altogether.

Mechanism

Ritonavir blocks CYP3A4 and CYP2C19, through which clopidogrel becomes its active metabolite. The active metabolite is not formed – antiplatelet effect is lost. Ritonavir also induces glucuronidation, further reducing clopidogrel activity.

Symptoms

The patient feels no symptoms – the weakened antiplatelet effect is silent. In patients with a coronary stent or after acute coronary syndrome: risk of recurrent myocardial infarction, stent thrombosis, and ischaemic stroke.

Management

Avoid the combination. Alternative antiplatelet: ticagrelor (no CYP2C19 activation needed). If ticagrelor is impossible: prasugrel (requires activation but via a different route) with caution.

Mechanism

Clopidogrel blocks the platelet P2Y12 receptor; rivaroxaban directly inhibits factor Xa. The two antithrombotic mechanisms add up, roughly doubling major bleeding risk.

Symptoms

Gum bleeding, epistaxis, bruising without trauma, blood in urine or stool, menorrhagia. Severe cases include gastrointestinal or intracranial haemorrhage. Risk rises in patients over 65 and with prior peptic ulcer disease.

Management

Dual therapy is used after acute coronary syndrome or stenting in atrial fibrillation, generally for no more than 1–6 months. Rivaroxaban dose is adjusted to age and renal function. PPI cover with pantoprazole is mandatory.

Mechanism

Clopidogrel and ticagrelor block the same platelet receptor, P2Y12. Clopidogrel acts through an active metabolite and binds irreversibly, so affected platelets stay switched off for 7-10 days; ticagrelor binds reversibly and needs no bioactivation. The pair adds no benefit: after a loading dose ticagrelor already suppresses aggregation almost fully, and no trial has tested two oral P2Y12 inhibitors together. ESC 2023 dual antiplatelet therapy is aspirin plus one P2Y12 inhibitor. Bleeding risk, meanwhile, is additive, as both product labels state.

Symptoms

Gum bleeding, epistaxis, bruising and haematomas after minor trauma, melaena, haematuria, a haemoglobin drop with no obvious source. Dyspnoea on ticagrelor is a drug effect of its own and usually has nothing to do with blood loss.

Management

Keep one P2Y12 inhibitor and stop the other the same day. Spacing the doses or halving both makes no sense. For acute-phase escalation, start ticagrelor with a 180 mg loading dose and drop clopidogrel at that moment, the way the 2017 international switching consensus describes it. For an elective switch outside the acute setting the Brilique SmPC gives a different anchor: the first dose 24 hours after the last dose of the other antiplatelet. On ticagrelor keep aspirin maintenance at or below 100 mg daily. Never stop both at once: premature withdrawal of antiplatelet therapy after an acute coronary syndrome raises the risk of infarction and death. After stopping the extra drug watch for bleeding over the next few days, and note that both labels require a 5-day pause before high-bleeding-risk procedures.

Mechanism

Warfarin blocks vitamin K-dependent clotting factor synthesis; clopidogrel inhibits platelet aggregation via the P2Y12 receptor. The two antithrombotic mechanisms add up.

Symptoms

Gum bleeding, epistaxis, bruising without trauma, blood in urine or stool, menorrhagia. Severe cases include gastrointestinal or intracranial haemorrhage. Risk rises in patients over 65 and with prior peptic ulcer disease.

Management

Combine only for clear indications (e.g., atrial fibrillation plus coronary stent). Limit dual therapy to 1–6 months depending on risk. Keep INR at the lower end of the target range (2.0–2.5) and provide PPI cover with pantoprazole.

Mechanism

Additive antiplatelet effect via different targets: aspirin irreversibly blocks platelet cyclooxygenase; clopidogrel inhibits the P2Y12 receptor. The combination causes more bleeding than aspirin alone: in the CURE trial, major bleeding occurred in 3.7% of patients on clopidogrel plus aspirin and in 2.7% on placebo plus aspirin (FDA Plavix label, Table 1).

Symptoms

Gum bleeding, epistaxis, bruising without trauma. Severe cases: GI bleeding.

Management

Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is given after an acute coronary syndrome (ACS) and after coronary stenting. After ACS the default duration is 12 months unless bleeding risk is high. If the patient has been event-free for 3–6 months and is not at high ischaemic risk, switching to a single antiplatelet agent should be considered; at high bleeding risk this may be considered after 1 month (ESC 2023). After elective stenting for chronic coronary syndrome the default is up to 6 months, or 1–3 months at high bleeding risk (ESC 2024). Aspirin 75–100 mg/day; the clopidogrel label advises against aspirin doses above 100 mg. A proton pump inhibitor (PPI) is recommended when the risk of gastrointestinal bleeding is increased. With clopidogrel, use pantoprazole: the label advises against omeprazole and esomeprazole because they reduce formation of clopidogrel's active metabolite.

Mechanism

Amiodarone weakly inhibits CYP2C19, the key enzyme that converts clopidogrel to its active metabolite. Effect is clinically minimal; no proven reduction in antiplatelet activity.

Symptoms

The combination usually causes no specific symptoms. Baseline clopidogrel bleeding risk and amiodarone bradycardia risk remain.

Management

No dose adjustment needed. After acute coronary syndrome, if antiplatelet activity is in doubt, consider switching to ticagrelor or prasugrel (CYP2C19-independent).

Mechanism

Clopidogrel blocks the P2Y12 receptor and ginkgo inhibits platelet-activating factor. Both act on aggregation through different routes, and the European monograph names antiplatelet agents explicitly among treatments with increased bleeding risk.

Symptoms

Bruising, bleeding gums, prolonged bleeding after minor wounds.

Management

Inform the cardiologist or neurologist who prescribed clopidogrel. If ginkgo is being taken without a firm indication, stopping it is the simple option. On dual antiplatelet therapy after a stent the margin is smaller still, and prior consultation stops being optional.

Mechanism

Ibuprofen, like other non-steroidal anti-inflammatory drugs (NSAIDs), can inhibit platelet aggregation and prolong bleeding time (ibuprofen SmPC); clopidogrel also prolongs bleeding time (clopidogrel SmPC). Ibuprofen itself can cause ulcers and gastrointestinal bleeding, and antiplatelet drugs raise the risk of such bleeding (ibuprofen SmPC). The US Food and Drug Administration (FDA) states that clopidogrel with NSAIDs increases the risk of gastrointestinal bleeding (clopidogrel FDA label). In patients who also take low-dose aspirin, ibuprofen may competitively reduce its effect on platelets; with occasional ibuprofen use a clinically relevant effect is unlikely (ibuprofen SmPC).

Symptoms

Bleeding gums, nosebleeds, bruising without injury, black tarry stools, blood in the urine, vomiting blood or coffee-ground material, abdominal pain. The risk of gastrointestinal bleeding is higher in older people, after a previous ulcer, especially one complicated by bleeding or perforation, and with higher ibuprofen doses (ibuprofen SmPC).

Management

Clopidogrel is used with caution with non-steroidal anti-inflammatory drugs (NSAIDs) (clopidogrel SmPC), and ibuprofen with special caution with antiplatelet drugs (ibuprofen SmPC). Use ibuprofen at the lowest effective dose for the shortest time needed to relieve symptoms (ibuprofen SmPC). For patients who need drugs that raise gastrointestinal risk, the ibuprofen SmPC advises considering gastroprotection with misoprostol or a proton pump inhibitor; for older patients and those with a history of ulcer it recommends such protection and a start at the lowest dose (ibuprofen SmPC). Warn the patient that bleeding may last longer on clopidogrel and ask them to report any unusual bleeding or abdominal symptoms at once (clopidogrel and ibuprofen SmPCs). Stop ibuprofen at once if gastrointestinal bleeding or an ulcer occurs (ibuprofen SmPC).

Mechanism

Clopidogrel blocks platelet aggregation via the P2Y12 receptor; sertraline impairs primary haemostasis by inhibiting platelet serotonin reuptake. Additive bleeding risk, mainly gastrointestinal.

Symptoms

Gum bleeding, epistaxis, bruising without trauma, black or tarry stools, haematuria. Higher risk in older patients, prior peptic ulcer disease, and chronic kidney disease.

Management

The combination is acceptable. In patients over 65 or with prior peptic ulcer disease, add gastroprotection — pantoprazole or esomeprazole 20 mg/day (avoid omeprazole — it suppresses clopidogrel activation). Antidepressant alternative without platelet effect: mirtazapine or agomelatine.

Mechanism

An early study (Lau et al., Circulation 2003) in 44 patients showed in vitro competition between atorvastatin and clopidogrel for CYP3A4. Subsequent large clinical trials (PROVE-IT, MIRACL, CHARISMA) did not confirm clinically significant attenuation of clopidogrel's antiplatelet activity.

Symptoms

The combination usually causes no specific symptoms. Each drug's individual side effects remain.

Management

Standard combination after acute coronary syndrome and in coronary artery disease. No dose adjustment needed. In patients at high risk of recurrent thrombosis with unclear antiplatelet activity, consider switching to ticagrelor or prasugrel (CYP3A4-independent).

Mechanism

Clopidogrel is a prodrug that needs CYP2C19 for activation, and its label lists the inhibitors to avoid: omeprazole and esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine, carbamazepine and efavirenz. Pantoprazole is not on that list, which is why it serves as the compatible PPI when the stomach needs protection without losing antiplatelet effect.

Symptoms

The combination produces no symptoms of its own. What is watched is bleeding from the antiplatelet itself: black stools, bruising, gum bleeding. A long PPI course adds hypomagnesaemia and lower vitamin B12, unrelated to clopidogrel.

Management

If a patient on clopidogrel needs a proton pump inhibitor, pantoprazole is suitable: the clopidogrel SmPC approved by the European Medicines Agency (EMA) states that clopidogrel can be given with pantoprazole, and the pantoprazole label approved by the US Food and Drug Administration (FDA) requires no clopidogrel dose change. Omeprazole and esomeprazole are avoided with clopidogrel (clopidogrel SmPC, EMA; clopidogrel label, FDA).